Jazz Pharmaceuticals
Open enrollment across a mixed-phase pipeline
According to ClinicalTrials.gov-derived indexes, Jazz Pharmaceuticals sits in the top decile of US sponsors by registered trial count (#212 of 15,742 sponsors by registered trial count).
Jazz Pharmaceuticals: 128 sponsored US clinical trials, 15 recruiting.
Jazz Pharmaceuticals sponsors 128 registered US clinical trials on ClinicalTrials.gov, 15 of them currently recruiting, and 81 completed. 50 of these trials are in Phase 3-4 (later-stage) and 69 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Narcolepsy, with 5 trials.
Top-decile sponsor footprint
Jazz Pharmaceuticals ranks in the top decile of sponsors by registered trial count (#212 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
81 of 108 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (75.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
128 total, page 3 of 3
Sativex® for Relieving Persistent Pain in Patients With Advanced Cancer
NCT01361607
Safety and Pharmacokinetics of CMX001 in Impaired Hepatic Function and Healthy Subjects
NCT05391724
Long Term Safety of Sativex Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Patients With Uncontrolled Persistent Chronic Cancer Related Pain
NCT01337089
Study to Assess Brincidofovir Treatment of Serious Diseases or Conditions Caused by Double-stranded DNA Viruses
NCT01143181
Phase 2 Study to Evaluate Brincidofovir for the Prevention of Adenovirus Disease
NCT01241344
Pilot/Ph I Safety and Efficacy of ODSH in Protein Losing Enteropathy Secondary to Single Ventricle Palliative Surgery
NCT01161641
A Safety, Tolerability and Pharmacokinetic Study of a Single Dose of CMX157 in Healthy Volunteers
NCT01080820
Safety and Tolerability Study Comparing Sodium Oxybate Given as an Oral Solution to a Single-blinded Combination of Oral Tablets Plus Oral Solution in Subjects With Fibromyalgia
NCT00803023
CMX001 in Post-transplant Patients With BK Virus Viruria
NCT00793598
Study of CMX001 to Prevent/Control Cytomegalovirus Infection in R+ Hematopoietic Stem Cell Transplant Recipients
NCT00942305
Trial of CPX-351 in Adult Patients With First Relapse Acute Myeloid Leukemia (AML)
NCT00822094
Comparative Bioavailability and Effect of Food on CMX001 in Healthy Volunteers
NCT00780182
Trial of CPX-351 in Newly Diagnosed Elderly AML Patients
NCT00788892
Study of Intranasal Clonazepam in Adult Subjects With Epileptic Seizures
NCT00594945
Defibrotide for Patients With Hepatic Veno-occlusive Disease: A Treatment IND Study
NCT00628498
Multiple-dose,Double-blind,Placebo-controlled Study of Sodium Oxybate in Patients With Essential Tremor
NCT00598078
A Study Designed to Evaluate ODSH in Subjects With Exacerbations of COPD
NCT00457951
A Safety and Efficacy Study of Xyrem® (Sodium Oxybate) to Treat Fibromyalgia.
NCT00423813
Safety and Efficacy Study of Xyrem® (Sodium Oxybate) in Subjects With Fibromyalgia.
NCT00423605
Multicenter Study of CPX-351(Cytarabine:Daunorubicin) Liposome Injection in Patients With Advanced Hematologic Cancer.
NCT00389428
A Safety and Efficacy Study of Xyrem® in Subjects With Fibromyalgia
NCT00371137
Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease in Hematopoetic Stem Cell Transplant Patients
NCT00358501
Multicenter Study Of CPX-1 (Irinotecan HCl: Floxuridine) Liposome Injection In Patients With Advanced Colorectal Cancer
NCT00361842
A Long-Term Study Continuing on From Study 04-001-01 of an Experimental Medication in Adults With Anxiety Disorder
NCT00106860
Experimental Medication For the Treatment of Generalized Anxiety Disorder
NCT00097708
Trial Comparing the Effects of Xyrem (Sodium Oxybate) With Placebo for the Treatment of Fibromyalgia
NCT00087555
Trial of Effects of Oral Xyrem and Zolpidem on Sleep-Disordered Breathing in Obstructive Sleep Apnea Patients
NCT00086281
Trial Comparing Effects of Xyrem Taken Orally and Modafinil With Placebo in Treating Daytime Sleepiness in Narcolepsy
NCT00066170
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 26 |
| Phase 2 | 43 |
| Phase 3 | 44 |
| Phase 4 | 6 |
Therapeutic Areas
What is open in the Jazz Pharmaceuticals pipeline
15 recruiting of 128 indexed (12% open); 81 completed (63%).
Phase mix: 50 late (III/IV) vs 69 early (I/II) (balanced across stages).
Top condition: Narcolepsy (5 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Jazz Pharmaceuticals: open-pipeline peers nationwide
Peers matched on 128 registered trials and 12% open enrollment, not the therapeutic-area sidebar.
Jazz Pharmaceuticals sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 128 trials (± recruiting share)
- University of Illinois at Urbana-Champaign · 129 trials · 14% recruiting
- Stony Brook University · 127 trials · 19% recruiting
- Rhode Island Hospital · 130 trials · 20% recruiting
- The Methodist Hospital Research Institute · 126 trials · 39% recruiting
Sponsors near 12% open enrollment (± trial volume)
- Cochlear · 12% recruiting · 34 trials
- Erchonia Corporation · 12% recruiting · 34 trials
- Hutchmed · 12% recruiting · 17 trials
- International Maternal Pediatric Adolescent AIDS Clinical Trials Group · 12% recruiting · 17 trials
Related
What to do with this Jazz Pharmaceuticals page
128 registered trials is a research-attention snapshot, not an endorsement of Jazz Pharmaceuticals or any single study.
- 15 of Jazz Pharmaceuticals's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Narcolepsy is the condition Jazz Pharmaceuticals studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Narcolepsy trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Jazz Pharmaceuticals pipeline card: 128 registered trials from official public datasets.Report a data error.